Patents by Inventor Tsuneo Yasuma

Tsuneo Yasuma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100197761
    Abstract: The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof. The compound or a salt thereof or a prodrug thereof has a GPR40 receptor function modulating action and is useful as an insulin secretagogue or an agent for the prophylaxis or treatment of diabetes and the like.
    Type: Application
    Filed: March 17, 2010
    Publication date: August 5, 2010
    Inventors: Tsuneo Yasuma, Nobuyuki Negoro, Masayuki Yamashita, Masahiro Itou
  • Publication number: 20100184794
    Abstract: The present invention aims to provide a glucokinase activator useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, obesity and the like, and the like. A glucokinase activator containing a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof.
    Type: Application
    Filed: October 17, 2007
    Publication date: July 22, 2010
    Inventors: Tsuneo Yasuma, Yasufumi Miyamoto
  • Publication number: 20100144806
    Abstract: A compound of the formula (I): wherein each symbol is as defined in the description, a salt s thereof, and a prodrug thereof of the present invention unexpectedly have a superior GPR40 receptor agonist activity and superior properties as pharmaceutical products such as stability and the like, and can be safe and useful pharmaceutical agents for the prophylaxis or treatment of GPR40 receptor-related pathology or diseases in mammals.
    Type: Application
    Filed: July 28, 2006
    Publication date: June 10, 2010
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tsuneo Yasuma, Nobuyuki Negoro
  • Publication number: 20100144702
    Abstract: The purpose of the present invention is to provide a glucokinase activator useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, obesity and the like. The present invention provides a glucokinase activator containing a compound represented by the formula (I): wherein R1 is a hydrogen atom or a halogen atom; R2 is a group represented by wherein each symbol is defined in the specification, or a salt thereof or a prodrug thereof.
    Type: Application
    Filed: October 18, 2007
    Publication date: June 10, 2010
    Inventors: Tsuneo Yasuma, Osamu Ujikawa, Masahiro Itoh, Kazuko Aoki
  • Patent number: 7732626
    Abstract: The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof. The compound or a salt thereof or a prodrug thereof has a GPR40 receptor function modulating action and is useful as an insulin secretagogue or an agent for the prophylaxis or treatment of diabetes and the like.
    Type: Grant
    Filed: June 26, 2007
    Date of Patent: June 8, 2010
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tsuneo Yasuma, Nobuyuki Negoro, Masayuki Yamashita, Masahiro Itou
  • Publication number: 20100137610
    Abstract: The purpose of the present invention is to provide a glucokinase activator useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, obesity and the like. The present invention provides a glucokinase activator containing a compound represented by the formula (I): wherein R1 is a hydrogen atom or a halogen atom; R2 is a group represented by wherein each symbol is defined in the specification, or a salt thereof or a prodrug thereof.
    Type: Application
    Filed: March 19, 2009
    Publication date: June 3, 2010
    Inventors: Tsuneo Yasuma, Osamu Ujikawa, Masahiro Itoh, Kazuko Aoki
  • Publication number: 20100130446
    Abstract: The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof. The compound of the present invention has a glucokinase activity, and is useful as a medicament such as an agent for the prophylaxis or treatment of diabetes, obesity and the like, and the like.
    Type: Application
    Filed: April 25, 2008
    Publication date: May 27, 2010
    Applicant: TAKEDA PHARMACEUTICAS COMPANY LIMITED
    Inventors: Tsuneo Yasuma, Kentaro Hashimoto, Masahiro Ito
  • Patent number: 7718798
    Abstract: The purpose of the present invention is to provide a glucokinase activator useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, obesity and the like. The present invention provides a glucokinase activator containing a compound represented by the formula (I): wherein R1 is a hydrogen atom or a halogen atom; R2 is a group represented by wherein each symbol is defined in the specification, or a salt thereof or a prodrug thereof.
    Type: Grant
    Filed: March 19, 2009
    Date of Patent: May 18, 2010
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tsuneo Yasuma, Osamu Ujikawa
  • Patent number: 7652133
    Abstract: The purpose of the present invention is to provide a glucokinase activator useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, obesity and the like. The present invention provides a glucokinase activator containing a compound represented by the formula (I): wherein R1 is a hydrogen atom or a halogen atom; R2 is a group represented by wherein each symbol is defined in the specification, or a salt thereof or a prodrug thereof.
    Type: Grant
    Filed: October 18, 2007
    Date of Patent: January 26, 2010
    Assignee: Takeda Pharmaceutical Company Limited
    Inventor: Tsuneo Yasuma
  • Publication number: 20100004312
    Abstract: The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof. The compound or a salt thereof or a prodrug thereof has a GPR40 receptor function modulating action and is useful as an insulin secretagogue or an agent for the prophylaxis or treatment of diabetes and the like.
    Type: Application
    Filed: June 26, 2007
    Publication date: January 7, 2010
    Inventors: Tsuneo Yasuma, Nobuyuki Negoro, Masayuki Yamashita, Masahiro Itou
  • Publication number: 20090286975
    Abstract: The purpose of the present invention is to provide a glucokinase activator useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, obesity and the like. The present invention provides a glucokinase activator containing a compound represented by the formula (I): wherein R1 is a hydrogen atom or a halogen atom; R2 is a group represented by wherein each symbol is defined in the specification, or a salt thereof or a prodrug thereof.
    Type: Application
    Filed: March 19, 2009
    Publication date: November 19, 2009
    Inventors: Tsuneo Yasuma, Osamu Ujikawa, Masahiro Itoh, Kazuko Aoki
  • Publication number: 20090247746
    Abstract: The present invention provides a glucokinase activator containing a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof. According to the present invention, a glucokinase activator useful as a pharmaceutical agent such as agent for the prophylaxis or treatment of diabetes, obesity and the like, and the like can be provided.
    Type: Application
    Filed: April 20, 2006
    Publication date: October 1, 2009
    Inventors: Tsuneo Yasuma, Osamu Ujikawa, Hidehisa Iwata
  • Patent number: 7585880
    Abstract: The present invention provides a novel compound having a GPR40 receptor function modulating action, which is useful as an insulin secretagogue, a drug for the prophylaxis or treatment of diabetes and the like. A compound represented by the formula (I) wherein each symbol is as defined in the specification, a salt thereof and a prodrug thereof have unexpectedly superior GPR40 receptor agonist activity and also show superior properties as a pharmaceutical product, such as stability and the like. Thus, they can be safe and useful drugs for the prophylaxis or treatment of GPR40 receptor related conditions or diseases in mammals.
    Type: Grant
    Filed: December 24, 2004
    Date of Patent: September 8, 2009
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tsuneo Yasuma, Shinobu Sasaki, Nozomu Sakai
  • Publication number: 20090215746
    Abstract: There is provided a calcium receptor modulator comprising a compound of the formula (I): wherein ring A is an optionally substituted 5- to 7-membered ring; ring B is an optionally substituted 5- to 7-membered heterocyclic ring; X1 is CR1, CR1R2, N or NR13; X2 is N or NR3; Y is C, CR4 or N, Z is CR5, CR5R6, N or NR7; Ar is an optionally substituted cyclic group; R is H, an optionally substituted hydrocarbon group, etc.; and is a single bond or a double bond; R1, R2, R3, R4, R5, R6, R7 and R13 are independently H, an optionally substituted hydrocarbon group; or a salt thereof or a prodrug thereof. Compounds of the formula (II) and (III): wherein ring A is an optionally substituted 5- to 7-membered ring; Q is C, CR5 or N; R8, R9, R10, R11 and R12 are independently, H, an optionally substituted hydrocarbon group, etc., or a salt thereof are also provided. Also specify X1, R3, R1, Y and X3 in formula (II) and (III) as before.
    Type: Application
    Filed: October 31, 2008
    Publication date: August 27, 2009
    Applicant: Takeda Pharmaceuticals Company Limited
    Inventors: Tsuneo Yasuma, Akira Mori, Masahiro Kawase, Hiroyuki Kimura, Masato Yoshida, Albert Charles Gyorkos, Scott Alan Pratt, Christopher Peter Corrette
  • Patent number: 7517910
    Abstract: The present invention aims at provision of a novel compound having a GPR40 receptor function modulating action, which is useful as an insulin secretagogue, an agent for the prophylaxis or treatment of diabetes and the like. The compound represented by the formula: wherein each symbol is as defined in the description, a salt thereof, and a prodrug thereof of the present invention unexpectedly have a superior GPR40 receptor agonistic activity and superior properties as pharmaceutical products such as stability and the like, and can be safe and useful pharmaceutical agents as agents for the prophylaxis or treatment of GPR40 receptor-related pathology or diseases in mammals.
    Type: Grant
    Filed: March 28, 2005
    Date of Patent: April 14, 2009
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tsuneo Yasuma, Shuji Kitamura, Nozomu Sakai
  • Patent number: 7514441
    Abstract: There is provided a calcium receptor modulator comprising a compound of the formula (I): wherein ring A is an optionally substituted 5- to 7-membered ring; ring B is an optionally substituted 5- to 7-membered heterocyclic ring; X1 is CR1, CR1R2, N or NR13; X2 is N or NR3; Y is C, CR4 or N, Z is CR5, CR5R6, N or NR7; Ar is an optionally substituted cyclic group; R is H, an optionally substituted hydrocarbon group, etc.; and ?is a single bond or a double bond; R1, R2, R3, R4, R5, R6, R7 and R13 are independently H, an optionally substituted hydrocarbon group; or a salt thereof or a prodrug thereof. Compounds of the formula (II) and (III): wherein ring A is an optionally substituted 5- to 7-membered ring; Q is C, CR5 or N; R8, R9, R10, R11 and R12 are independently, H, an optionally substituted hydrocarbon group, etc., or a salt thereof are also provided. Also specify X1, R3, R1, Y and X3 in formula (II) and (III) as before.
    Type: Grant
    Filed: August 21, 2003
    Date of Patent: April 7, 2009
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tsuneo Yasuma, Akira Mori, Masahiro Kawase, Hiroyuki Kimura, Masato Yoshida, Albert Charles Gyorkos, Scott Alan Pratt, Christopher Peter Corrette
  • Publication number: 20090012093
    Abstract: The GPR40 receptor function regulator of the present invention, which comprises a compound having an aromatic ring and a group capable of releasing cation is useful as an insulin secretagogue or an agent for the prophylaxis or treatment of diabetes and the like.
    Type: Application
    Filed: November 6, 2003
    Publication date: January 8, 2009
    Inventors: Kohji Fukatsu, Shinobu Sasaki, Shuji Hinuma, Yasuaki Ito, Nobuhiro Suzuki, Masataka Harada, Tsuneo Yasuma
  • Patent number: 7456218
    Abstract: The present invention provides a novel compound represented by the formula (I) wherein each symbol is as defined in the specification, a salt thereof and a prodrug thereof having a superior GPR40 receptor function modulating action, which can be used as an insulin secretagogue, an agent for the prophylaxis or treatment of diabetes and the like. They unexpectedly show superior GPR40 receptor agonist activity, and also show superior properties as a pharmaceutical product, such as stability and the like. Thus, they can be safe and useful pharmaceutical agents for the prophylaxis or treatment of GPR40 receptor related diseases in mammals.
    Type: Grant
    Filed: December 24, 2004
    Date of Patent: November 25, 2008
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tsuneo Yasuma, Shuji Kitamura, Nobuyuki Negoro
  • Publication number: 20080269220
    Abstract: A compound represented by the formula (1): wherein each symbol is as defined in the specification, and a salt thereof and a prodrug thereof unexpectedly have superior GPR40 receptor agonist activity, superior in the properties as a pharmaceutical product such as stability and the like, and can be a safe and useful pharmaceutical agent as a drug for the prophylaxis or treatment of GPR40 receptor related pathology or diseases such as diabetes and the like.
    Type: Application
    Filed: March 14, 2005
    Publication date: October 30, 2008
    Inventors: Tsuneo Yasuma, Nobuyuki Negoro, Shinobu Sasaki
  • Publication number: 20080146602
    Abstract: A compound represented by the formula (I) wherein R is a hydrogen atom or a C1-4 alkyl group, and X is CH2, O or S, or a salt thereof. The present invention provides a novel thienopyridine derivative having an anti-inflammatory effect, a bone resorption suppressing effect, an immune cytokine production suppressing effect and the like, and useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of arthritis such as rheumatoid arthritis and the like, and the like, and the like.
    Type: Application
    Filed: May 13, 2005
    Publication date: June 19, 2008
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Atsuo Baba, Tsuneo Yasuma, Hiroyuki Tawada, Makoto Yamashita